Molecular Templates announced the initiation of a single-agent Phase 2 study of MT-3724, a CD20-targeted ETB, in relapsed/refractory diffuse large B-cell lymphoma, or DLBCL, patients. This multicenter study will enroll up to 100 patients, in a staged manner, who have received at least two standard of care treatment regimens for DLBCL. As a monotherapy study in heavily pretreated patients, this study has the potential to be pivotal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.